Edgewise Therapeutics options flow shows lopsided call activity
Edgewise Therapeutics (EWTX) saw significant options activity, with a 6,000-contract diagonal spread indicating a bullish stance. Traders rolled ITM Sep $45 calls to OTM Oct $50 calls, targeting an 8.4% rally. EWTX stock is up 197% over the past year, driven by a $2.65B business sale. Analysts have mixed views on its valuation and profitability.
How this was made
The 30-second read
Why it matters
The transaction dramatically improves the balance sheet, prompting aggressive call buying and a roll to higher strikes, suggesting a short‑term upside thesis.
Market read
The sale and options flow provide a clear catalyst for EWTX's near‑term price action, making the stock a potential short‑term trade.
What to watch
Edgewise remains unprofitable with weak margins; cash may not translate into near‑term earnings growth.
Background
Edgewise Therapeutics (EWTX) is a small‑cap biotech that recently sold its muscular dystrophy assets for $2.65B.
Ticker impact
Edgewise Therapeutics completed a $2.65B sale of its muscular dystrophy business to Servier, driving a bullish options roll to $50 calls.
Potential move toward $50 within weeks, upside of ~8% from current $46 level.
Large cash transaction plus lopsided call buying indicates informed bullish positioning.
Market effects
Biotech sector may see increased optimism for cash‑rich peers after a major divestiture.
US biotech indices could gain modestly as Edgewise's move lifts sentiment.
Limited to biotech investors; no broad market effect.
Counterpoint
If momentum stalls near the 52‑week high, the $50 calls could expire worthless, exposing buyers to loss.
Key entities
- companyEdgewise Therapeutics
Biotech firm completing a $2.65B asset sale.
- companyServier
French pharma buyer of Edgewise's muscular dystrophy business.
